Intravenous therapy for advanced heart failure

Current Opinion in Cardiology

Volumn 15, Issue 3, 2000, Pages 156-160

  Stanek, Brigitte ^a   Pacher, Richard ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENOXIMONE; HYDRALAZINE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; METOPROLOL; MILRINONE; NITRIC ACID DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN E1; VASODILATOR AGENT;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; LONG-TERM CARE; PATIENT SELECTION; PRACTICE GUIDELINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASODILATOR AGENTS; WAITING LISTS;

EID: 0034127693     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200005000-00006     Document Type: Review

References (21)

1. 1 Remme WJ: Prevention of worsening heart failure: future focus. Eur Heart J 1998, 19 (suppl B):B47-B53. A comprehensive overview of drugs that lead to prevention of worsening heart failure.
2. 2 Berger R, Kuchling G, Frey B, Grimm M, Laufer G, Pacher R, et al.: Prognostic value of low versus high dosage of angiotensin converting enzyme inhibitors in patients awaiting heart transplantation. J Heart Lung Transplant 2000;19:127-33.
3. 3 Stevenson LW: Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Failure 1999, 1:251-257. Guidelines for when to measure hemodynamics directly and how to tailor therapy to measured hemodynamics. Treatment benefits beyond hemodynamically tailored therapy are also briefly discussed.
4. 4 Leier CV, Binkley PF: Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998, 41:207-224. This article reviews the traditional use of dobutamine, dopamine, and intravenous milrinone for decompensated advanced heart failure and provides an objective attitude toward the controversial "intermittent infusion" approach. Based mainly on the authors' own findings, current applications are critically debated and recommendations are given, including those for the nontransplantable heart failure patient.
5. 5 Delehanty J, Liang CS, Odorosi ML: Effects of dobutamine on ischemic vasodilation of the forearm in patients with severe congestive heart failure. J Card Fail 1999, 5:25-30.
6. 6 Elis A, Bental T, Kimchi O, Ravid M, Lishner M: Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998, 63:682-685.
7. 7 Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, et al., for the DICE (Dobutamina nell'Insufficienza Cardiaca Estrema) Investigators: Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. Am Heart J 1999, 138:247-253.
8. 8 O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78-86.
9. 9 Cusick DA, Pfeifer PB, Quigg RJ: Effects of intravenous milrinone followed by titration of high dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Am J Cardiol 1998, 82:1060-1065.
10. 10 Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, et al.: Combined oral positive inotropic and β-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998, 31:1336-1340. Small pilot study suggesting that oral enoximone may help to wean patients from dobutamine infusions and to facilitate the initiation of β-blocker therapy aimed at preventing or delaying heart transplantation.
11. 11 DeMarco T, Chatterjee K: Phosphodiesterase inhibitors in refractory heart failure: bridge to beta-blockade? J Am Coll Cardiol 1998, 1341-1343.
12. 12 Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO: Current medical therapy for advanced heart failure. Am Heart J 1998, 132:S231-S248. This article covers the complete armentarium of oral and intravenous drugs for the treatment of advanced heart failure. Also, the design of the Outcome of a Prospective Trial of Intravenous Milrinone for Exacerbation of Chronic Heart Failure (OPTIME CHF) trial is presented.
13. 13 Park HH, Young JB, Hobbs RE, Haas GJ, Goormastik N, Boporai RC: The use of home inotropic therapy for patients awaiting cardiac transplant: analysis of a nationwide survey among U.S. Cardiac Transplant Centers. J Heart Lung Transplant 1998, 17(Abstr Suppl):43.
14. 14 Winkel E, Kao W, Fisher SG, Heroux AL, Johnson MR, Costanzo MR: Outpatient inotropic therapy in heart transplant candidates: should its use influence waiting list priority status ? J Heart Lung Transplant 1998, 17:809-816. Retrospective analysis of the pretransplantation outcomes of heart transplantation candidates initially listed as status 2 according to the current United Network for Organ Sharing (UNOS) heart allocation system, comparing those receiving intravenous outpatient inotropic therapy with those maintained on oral heart failure agents alone.
15. 15 Pacher R, Stanek B: Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience. Eur J Heart Failure 1999, 1:263-268. Review of the authors' 10-year experience with ambulatory vasodilator and inodilator therapy (dobutamine, dopamine, and prostaglandin E1) and published reports from international heart failure centers (including those who use intravenous phosphodiesterase inhibitors).
16. 16 Wimmer A, Stanek B, Kubecova L, Vitovec J, Spinar J, Yilmaz N, et al.: Effects of prostaglandinE1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Jpn Heart J 1999, 40:311-334.
17. 17 Stanek B, Sturm B, Frey B, Hülsmann M, Bojic A, Berger R, et al.: Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 1999, 18:358-366.
18. 18 Ewy GA: Inotropic infusions for chronic congestive heart failure. Medical miracles or misguided medicinals ? J Am Coll Cardiol 1999, 33:572-575. This is a critical comment on the current use of inotropic infusions for the management of both inpatient and outpatient chronic heart failure. The author presents the view that this therapy should only be recommended as temporary support for stunned or hibernating myocardium that has been revascularized, for an acutely ill patient until it is determined that there is a treatable or reversible cause, or as a bridge to cardiac transplantation.
19. 19 Cesario D, Clark J, Maisel A: Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998, 135:121-129.
20. 20 Hatzizacharias A, Makris T, Krespi P, Triposkiadis F, Voyatzi P, Dalianis N, et al.: Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J 1999, 138:241-246.
21. 21 Silver MA: Intermittent inotropes for advanced heart failure: Inquiring minds want to know. Am Heart J 1999, 138:191-192.